Based on the BioLife Solutions Inc stock forecast from 9 analysts, the average analyst target price for BioLife Solutions Inc is USD 30.07 over the next 12 months. BioLife Solutions Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of BioLife Solutions Inc is Slightly Bearish, which is based on 3 positive signals and 6 negative signals. At the last closing, BioLife Solutions Inc’s stock price was USD 26.61. BioLife Solutions Inc’s stock price has changed by +0.72% over the past week, +1.10% over the past month and +53.11% over the last year.
No recent analyst target price found for BioLife Solutions Inc
No recent average analyst rating found for BioLife Solutions Inc
Company Overview BioLife Solutions Inc
BioLife Solutions, Inc. develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line that comprises of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides cryogenic freezer technology for controlled rate freezing and cryogenic storage of biologic materials; ultra-low temperature mechanical freezers; evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage and transport services. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington. Read Less
BioLife Solutions, Inc. develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research,...Read More
Frequently Asked Questions About BioLife Solutions Inc (BLFS) Stock
Based on ratings from 9 analysts BioLife Solutions Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 14 buy, sell and hold ratings.
Unfortunately we do not have enough data on BLFS's stock to indicate if its a good dividend stock.
Based on targets from 9 analysts, the average taret price for BLFS is USD 30.07 over the next 12 months. The maximum analyst target price is USD 34 while the minimum anlayst target price is USD 26.
BLFS stock's Price/Earning ratio is 185.00.
Our analysis grades BLFS stock's Price / Earning ratio at F. This means that BLFS stock's Price/Earning ratio is above 89% of the stocks in the Medical Instruments & Supplies sector in the NSD exchange.
Based on this BLFS may be a overvalued for its sector.
The last closing price of BLFS's stock was USD 26.61.
The most recent market capitalization for BLFS is USD 1.23B.
Based on targets from 9 analysts, the average taret price for BLFS is projected at USD 30.07 over the next 12 months.
This means that BLFS's stock price may go up by +13.01% over the next 12 months.
We can't find any ETFs which contains BioLife Solutions Inc's stock.
As per our most recent records BioLife Solutions Inc has 409 Employees.
BioLife Solutions Inc's registered address is 3303 Monte Villa Parkway, Bothell, WA, United States, 98021.
You can get more information about it from BioLife Solutions Inc's website at https://www.biolifesolutions.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low debt
The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About BioLife Solutions Inc (BLFS) Stock
Based on ratings from 9 analysts BioLife Solutions Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 14 buy, sell and hold ratings.
Unfortunately we do not have enough data on BLFS's stock to indicate if its a good dividend stock.
Based on targets from 9 analysts, the average taret price for BLFS is USD 30.07 over the next 12 months. The maximum analyst target price is USD 34 while the minimum anlayst target price is USD 26.
BLFS stock's Price/Earning ratio is 185.00.
Our analysis grades BLFS stock's Price / Earning ratio at F. This means that BLFS stock's Price/Earning ratio is above 89% of the stocks in the Medical Instruments & Supplies sector in the NSD exchange.
Based on this BLFS may be a overvalued for its sector.
The last closing price of BLFS's stock was USD 26.61.
The most recent market capitalization for BLFS is USD 1.23B.
Based on targets from 9 analysts, the average taret price for BLFS is projected at USD 30.07 over the next 12 months.
This means that BLFS's stock price may go up by +13.01% over the next 12 months.
We can't find any ETFs which contains BioLife Solutions Inc's stock.
As per our most recent records BioLife Solutions Inc has 409 Employees.
BioLife Solutions Inc's registered address is 3303 Monte Villa Parkway, Bothell, WA, United States, 98021.
You can get more information about it from BioLife Solutions Inc's website at https://www.biolifesolutions.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for BLFS !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
